Dr Judy Garber outlines some of the genes that have recently been connected with cancer prevalence, and explains the implications of these newly identified cancer sub-types.

Dr Garber also considers the potential benefits of gene sequencing but warns of the potentially prohibitive cost of personalised medicines.